HEAL — Restart Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- CA$3.42m
- CA$3.16m
Annual cashflow statement for Restart Life Sciences, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -25.2 | -2.68 | -2.47 | -1.22 | 0.225 |
| Depreciation | |||||
| Non-Cash Items | 24.3 | 0.104 | 1.02 | 0.353 | -0.576 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.021 | 0.63 | -0.002 | 0.591 | 0.277 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.857 | -1.95 | -1.44 | -0.278 | -0.072 |
| Other Investing Cash Flow Items | 2.9 | 0.03 | 0 | — | — |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 2.9 | 0.03 | 0 | — | — |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | — | — | 1.49 | 0.019 | 0.075 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.05 | -1.92 | 0.048 | -0.258 | 0.003 |